Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8649337 | 0.76 | CYP2A6 (0.60) | CYP2A6ALDH1A1RORB | |
| SCHEMBL28311793 | 0.76 | CYP2A6 (0.55) | CYP2A6ALDH1A1RORB | |
| SCHEMBL18985992 | 0.76 | TDP1 (0.48) | CYP2A6ALDH1A1TSHRCYP3A4TP53 | |
| SCHEMBL8440654 | 0.73 | RXRA (0.54) | CYP2A6MAP4K4RORB | |
| SCHEMBL7451509 | 0.72 | CYP2A6 (0.56) | CYP2A6MAP4K4ALDH1A1CYP3A4RORB | |
| SCHEMBL2480042 | 0.72 | CYP3A4 (0.36) | CYP2A6ALDH1A1RECQLTSHRCYP3A4 | |
| SCHEMBL3128389 | 0.71 | CYP3A4 (0.53) | CYP2A6ALDH1A1BRD4TSHRCYP3A4 | |
| SCHEMBL3363485 | 0.71 | CYP2A6 (0.58) | CYP2A6MAOAMAP4K4ALDH1A1RECQL | |
| SCHEMBL6873402 | 0.71 | CYP2A6 (0.42) | CYP2A6MAOAALDH1A1TSHRCYP3A4 | |
| SCHEMBL2023695 | 0.71 | MAOA (0.68) | MAOAMAP4K4ALDH1A1RECQLBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. | 2009-08-13 | — | — | US | disclosed |
| WO-2007130743-A2 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-7294616-B2 | Capreomycin derivatives and their use as antibacterials | ARRAY BIOPHARMA, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2006052499-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060094644-A1 | Capreomycin derivatives and their use as antibacterials | ARRAY BIOPHARMA, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | CAPRIN1, NISCH, RPIA | CYP2A6 769/4885MAOA 2554/4885MAP4K4 3020/4885 |
| US-20060094644-A1 | Capreomycin derivatives and their use as antibacterials | SPOUT1, CAPRIN1, FBL | CYP2A6 1934/4885MAOA 1940/4885MAP4K4 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.